Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID-19 pandemic

Meerwein, Christian M; Stadler, Thomas M; Balermpas, Panagiotis; Soyka, Michael B; Holzmann, David

Abstract: Objectives The COVID-19 pandemic bears the risk of delayed cancer diagnoses. Methods Study on the diagnostic pathway of sinonasal malignancies during the COVID-19 pandemic. Results Median time from first symptom to treatment initiation was not increased during the pandemic: 137 days (interquartile range [IQR] 104-193) vs 139 days (IQR 103-219) (P = .60). Median time from first appointment at our institution to treatment initiation was even reduced in 2020: 18 days (IQR 11-25) vs 11 days (IQR 7-17) (P = .02). A trend toward advanced tumor stages during the pandemic was seen: 11/30 patients (36.7%) stage 4 in 2018 to 2019 vs 12/19 patients (63.2%) stage 4 in 2020 (P = .064). Conclusion Both, time to diagnosis and time to treatment initiation were similar during the pandemic. However, a higher proportion of advanced tumors stages was observed. Despite the pandemic, we provided a swift diagnostic workflow, including a virtual tumor board decision and a prompt treatment initiation. Level of Evidence: 4.

DOI: https://doi.org/10.1002/lio2.640

Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-209265
Journal Article
Published Version

The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.

Originally published at:
Meerwein, Christian M; Stadler, Thomas M; Balermpas, Panagiotis; Soyka, Michael B; Holzmann, David (2021). Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID-19 pandemic. Laryngoscope Investigative Otolaryngology, 6(5):904-910.
DOI: https://doi.org/10.1002/lio2.640
Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID-19 pandemic

Christian M. Meerwein MD1,2 | Thomas M. Stadler MD1,2 | Panagiotis Balermpas MD2,3 | Michael B. Soyka MD1,2 | David Holzmann MD1,2

1Department of Otorhinolaryngology, Head & Neck Surgery, University Hospital Zurich, Zurich, Switzerland
2University of Zurich, Zurich, Switzerland
3Department of Radiation Oncology, University Hospital Zurich, Zurich, Switzerland

Correspondence
Christian M. Meerwein, MD, Department of Otorhinolaryngology, Head & Neck Surgery, University Hospital Zurich, Frauenklinikstrasse 24, Zurich 8091, Switzerland.
Email: christian.meerwein@usz.ch

Abstract
Objectives: The COVID-19 pandemic bears the risk of delayed cancer diagnoses.
Methods: Study on the diagnostic pathway of sinonasal malignancies during the COVID-19 pandemic.
Results: Median time from first symptom to treatment initiation was not increased during the pandemic: 137 days (interquartile range [IQR] 104-193) vs 139 days (IQR 103-219) (P = .60). Median time from first appointment at our institution to treatment initiation was even reduced in 2020: 18 days (IQR 11-25) vs 11 days (IQR 7-17) (P = .02). A trend toward advanced tumor stages during the pandemic was seen: 11/30 patients (36.7%) ≥ stage 4 in 2018 to 2019 vs 12/19 patients (63.2%) ≥ stage 4 in 2020 (P = .064).
Conclusion: Both, time to diagnosis and time to treatment initiation were similar during the pandemic. However, a higher proportion of advanced tumors stages was observed. Despite the pandemic, we provided a swift diagnostic workflow, including a virtual tumor board decision and a prompt treatment initiation.

Level of Evidence: 4.

Keywords
delay, malignancy, nasal vestibule carcinoma, nasopharyngeal carcinoma, pandemic, sinonasal, tumor

1 INTRODUCTION

Among many other challenges in patient management, the recent COVID-2019 pandemic with months of national lockdowns in many countries worldwide bears a substantial risk of delayed cancer diagnosis.1 Possible reasons for a delay in the oncological pathway are both, patient and health care system related. Screening, case identification, and referral in symptomatic cancer have all been affected by the pandemic.2 Along with the call for social distancing, many patients have postponed their medical appointments, since they fear healthcare interactions or mistakenly believe, that health care systems are shut to all but COVID-19 patients.3 With regard to three common cancers (a. breast, b. colorectal, and c. lung) recent data indicated a significant decline in newly diagnosed patients during the pandemic.4,5 For head and neck cancer, the sixth most common cancer worldwide, which typically reveals a short tumor volume doubling time, a delayed treatment initiation was shown to significantly impact overall survival (OS) for patients undergoing upfront surgery or radiotherapy (RT).6,7 For sinonasal...
malignancies in particular, specific data on incidence and stage distribution during the pandemic is rare.\(^8\) Owing to their growth pattern, characterized by locally aggressive expansion and close relationship to pivotal neuro-vascular structures, patients often present at an advanced T category, with involvement of dura, orbit, or brain. Based on these facts, most institutions advocate for initiation of head and neck cancer treatment within 4 to 6 weeks of diagnosis.\(^7\) With this study on the diagnostic pathway and management of sinonasal malignancies during the COVID-19 pandemic in Switzerland, we aimed to compare the pandemic era (2020) to the prepandemic years (2018-2019). In particular, we wanted to investigate absolute numbers of newly diagnosed rhinologic tumors, time from first symptom to diagnosis and treatment initiation, time from first appointment at our institution to treatment initiation and a possible stage migration to more advanced tumors during the pandemic.

2 | METHODS

2.1 | Study design

This study received ethical approval from the ethics committee of the Canton of Zurich, Switzerland. Patients with documented denial to contribute personal health-related data to research were not included. We retrospectively reviewed a consecutive cohort of patients treated for sinonasal malignancies (primary sinonasal tumor, nasopharyngeal carcinoma, and nasal vestibule carcinoma) at the department of otorhinolaryngology at the University Hospital Zurich (Switzerland) between January 2018 and December 2020. The cohort was divided into two groups: control group (prepandemic era, January 2018-December 2019) vs index group (pandemic era, January 2020-December 2020). Patients with documented denial to contribute personal health-related data to research were not included. Tumors were staged according to the eighth edition of the American Joint Committee on Cancer staging system.\(^10\)

Patients underwent endonasal-endoscopic biopsy and exploration of the tumor under general anesthesia. In all patients, staging of the neck was performed with ultrasound-guided fine needle aspiration cytology (FNAC) of suspicious lymph nodes. Cross-sectional imaging with computed tomography (CT), magnetic resonance imaging (MRI), and hybrid positron-emission tomography (PET) imaging was performed. Treatment plans were discussed at our multidisciplinary tumor board.

2.2 | Patient characteristics, treatment protocols, outcome measures, and follow-up

The following patient data and tumor data were collected: age, gender, risk factors, history of SARS-COV19-infection (patient, close social environment), symptoms at initial presentation, onset of first symptoms, first contact with family doctor, first contact with private ENT, first contact at University Hospital Zurich (tertiary referral center), date of biopsy, initial clinical classification (cT, cN, cM), tumor stage, time from first diagnosis to biopsy (days), time from first symptom to treatment initiation at our institution (days), time from first contact at our institution to treatment initiation (days), histopathological work-up, location of primary tumor, primary treatment protocols, duration of follow up (months), and state at last follow-up. Of note: Only patients with terminated initial treatment protocols were included for the follow up calculation (45/49 patients).

2.3 | Variables and statistical analysis

The normality of distribution was checked using the Kolmogorov-Smirnov test. Data are either presented as median and interquartile range (IQR) or as mean ± standard deviation (SD), depending on the normality of data distribution. Differences between intervals (first symptom to biopsy, first symptom to treatment initiation, first appointment at our institution to treatment initiation) in the control group (2019-2019) and the index group (2020) were calculated using the Mann-Whitney U-test. Differences among the control and index group regarding the distribution of initial tumor stage were calculated using contingency tables and Fisher’s exact test. Accordingly, symptoms at initial presentation among different tumor stages were compared. A post-hoc analysis for the given sample and alpha level of .05 using “clincalc.com” was performed. The end of follow-up was December 2020. A P-value less than .05 indicated significance. Statistics used SPSS version 22 (IBM, Armonk, New York).

3 | RESULTS

3.1 | Patient and tumor characteristics

A total of 49 consecutive patients were included: prepandemic era (30 patients, 2018-2019) vs pandemic era (19 patients, 2020). The
absolute numbers of newly diagnosed tumors in 2020 was slightly higher, when compared to the two previous years (19 patients 2020 vs 30 patients 2018-2019). Figure 1 displays details on the distribution pattern of new tumor diagnoses during the year 2020 in relation to the national lockdown. None of the included patients or their close relatives in the pandemic group had a past medical history of documented COVID-19 infection or quarantine. Symptoms at initial presentation are presented in Table 1: although we observed a trend toward an increased prevalence of manifest symptoms along with advanced tumor stage, there was no statistically significant association.

### Table 1: Distribution of symptoms depending on initial tumor stage

| Symptoms          | Total | I   | II  | III | IV  | Fisher’s Exact Test (P value) |
|-------------------|-------|-----|-----|-----|-----|-----------------------------|
| Nasal obstruction | 29    | 2   | 10  | 4   | 13  | .122                        |
| Epistaxis         | 28    | 4   | 8   | 5   | 11  | .653                        |
| Hyposmia          | 5     | 0   | 1   | 0   | 4   | .582                        |
| Pain              | 18    | 3   | 1   | 2   | 12  | .064                        |
| Double vision     | 4     | 0   | 0   | 0   | 2   | .281                        |

### Table 2: Patients and tumor characteristics

| Characteristics | Total | 2020 | 2018-2019 |
|-----------------|-------|------|-----------|
| Number of patients (n) | 49    | 19   | 30        |
| Gender (n)      |       |      |           |
| Female          | 19    | 6    | 13        |
| Male            | 30    | 13   | 17        |
| Age at diagnosis (median, 1-3. IQR) | 66 | 52  | 70  |
|                 | (IQR 47-74) | (IQR 45-72) | (IQR 53-74) |
| Risk factors (n) |       |      |           |
| Smoking         | 19/49 | 7/19 | 12/30     |
| Wood dust exposure | 6/49 | 4/19 | 2/30     |
| Leather dust exposure | 1/49 | 0/19 | 1/30     |
| Entity (n)      |       |      |           |
| Nasopharyngeal carcinoma | 11 | 7    | 4        |
| Nasal vestibule carcinoma | 8  | 1    | 7        |
| Primary sinonasal tumor | 30 | 11   | 19       |
| Initial clinical T classification according to clinical and radiological assessment (n) | | | |
| cT1              |       |      |           |
| cT2              | 9     | 2    | 7         |
| cT3              | 10    | 2    | 8         |
| cT4              | 9     | 5    | 4         |
| 21               | 10    | 11   |           |
| Initial N classification (n) |       |      |           |
| cN0              | 40    | 13   | 27        |
| cN+              | 9     | 6    | 3         |
| Initial M classification (n) |       |      |           |
| cM0              | 45    | 17   | 28        |
| cM1              | 4     | 2    | 2         |
adenocarcinoma in 7/30 patients, SCC in 7/30 patients, sinonasal undifferentiated carcinoma (SNUC) in 6/30 patients, sinonasal mucosal melanoma in 6/30 patients, olfactory neuroblastoma in 3/30 patients and adenoidcystic carcinoma in 1/30 patient. As seen in Table 3, 30/49 patients presented with stage III or stage IV disease. When comparing the prepandemic group and the pandemic group with regard to tumor stage, we observed a trend toward tumor stage migration to more advanced tumors in 2020: 11/30 patients (36.7%) ≥ stage 4 in 2018 to 2019 vs 12/19 patients (63.2%) ≥ stage 4 in 2020 (P = .064; Table 3, Figure 2).

### 3.2 | Time to diagnosis, time to treatment initiation, and time to treatment initiation at tertiary referral center

As indicated in Table 4 and Figure 3, both, median time from first symptom to biopsy proven diagnosis and median time from first symptom to treatment initiation were similar in the prepandemic and the pandemic group. However, time interval from the first referral to tertiary referral center was significantly different.

#### TABLE 3  Distribution of tumor stage across the prepandemic group (2018-2019) and the pandemic group (2020)

| Year       | Stage | I | II | III | IV | < IV | ≥ IV |
|------------|-------|---|----|-----|----|------|-----|
| 2018-2019  |       | 6 | 8  | 5   | 11 | 19   | 11  |
| 2020       |       | 1 | 4  | 2   | 12 | 7    | 12  |

Fisher’s Exact Test: $P = .318$ $P = .064$

#### TABLE 4  Overall and stage dependent distribution of investigated intervals

| Interval                        | Stage | I        | II       | III      | IV       | Median       | Mann-Whitney-U |
|--------------------------------|-------|----------|----------|----------|----------|--------------|----------------|
| Symptom-Biopsy                 |       | 134 (113-162) | 123 (100-140) | 148 (82-187) | 101 (71-124) | 123 (82-156) | P = .17         |
| 2018-2019                      | Median, IQR | 190         | 115 (91-179) | 177 (73-195) | 116 (99-171) | 129 (104-192) | P = .02 |
| Symptom-Initiation of treatment|       | 179 (148-205) | 138 (110-195) | 143 (113-237) | 116 (88-151) | 137 (104-193) | P = .61         |
| 2018-2019                      | Median, IQR | 219         | 172 (138-207) | 188 (71-213) | 127 (97-171) | 139 (103-219) | P = .02         |
| First referral-Initiation of treatment |       | 17 (11-35) | 13 (12-21) | 28 (25-28) | 18 (8-27) | 18 (11-25) | P = .02 |
| 2018-2019                      | Median, IQR | 29          | 11 (11-15) | 8 (5-12) | 8 (5-15) | 11 (7-17) | P = .02         |

#### FIGURE 2  Distribution pattern of the initial tumor stage (stage I-IV) in the prepandemic (A, 2018-2019, a total of 30 newly diagnosed tumors) vs the pandemic era (B, 2020, a total of 19 newly diagnosed tumors)

#### FIGURE 3  In this study, we investigated (a) time from first symptom to biopsy proven diagnosis, (b) time from first symptom to treatment initiation, and (c) time from first referral to our institution to treatment initiation. USZ: University Hospital of Zurich, Switzerland
appointment at our institution to treatment initiation was significantly shorter during the pandemic, when compared to the prepandemic era.

3.3 | Primary treatment protocols

Initial treatment protocols consisted of surgery alone in 6/49 patients, neoadjuvant chemotherapy + definitive radiochemotherapy in 10/49 patients, surgery + adjuvant radiochemotherapy in 22/49 patients, primary radiochemotherapy in 10/49 patients, and best supportive care in one patient.

3.4 | Follow-up, outcome

The overall median follow up of the cohort was 15 months (IQR 7-23). For the control group (2018-2019), the median follow up was 22 months (IQR 15-25), while for the pandemic group, it was 4 months (IQR 4-7).

In the prepandemic group, most of the patients were free of disease at the last follow up (23/30, 79.3%). Seven patients (21.1%) had developed local persistence or recurrence, of whom two patients (6.8%) had synchronous distant metastases.

4 | DISCUSSION

4.1 | Main findings

In this tertiary referral center study on the management of sinonasal malignancies in the COVID-19 era in Switzerland we found that both, absolute time to biopsy proven diagnosis and time to treatment initiation were similar during the pandemic, when compared to prepandemic years. However, an increased proportion of advanced tumors stages (≥ stage 4) as possible indirect indicator of diagnostic delay prior to referral to the tertiary cancer center was observed. Despite the pandemic, we were able to provide a targeted and swift oncological treatment path at our institution, which included an interdisciplinary tumor board discussion in all cases and even resulted in a decreased time from first appointment to treatment initiation. Importantly, even during the two pandemic-“waves” during spring and late autumn 2020, no tumor boards were cancelled or delayed and all sessions were held virtually. The absolute number of newly diagnosed sinonasal tumors in 2020 was not lower, when compared to the two previous years.

The COVID-19 pandemic is a tremendous challenge for health care systems worldwide. Along with the burden of the disease, national wide lockdowns and limited health care system resources have secondarily complicated access to medical care and postponed urgently indicated medical treatments. For instance, in the United Kingdom, national cancer screening programs, which accounted for approximately 5% of all annual cancer diagnoses, have been suspended. The Netherlands Cancer Registry reported declining cancer incidence rates up to 40% at the peak of the pandemic. Additionally, data showed that patients with recently diagnosed cancer had significantly increased risk of COVID-19. For head and neck cancer and sinonasal malignancies in particular, only limited data on the sequelae of the pandemic are available so far. Data from the COVIDSurg collaborative estimated a 12-week cancellation rate of 38.9% for head and neck cancer surgery, while for benign head and neck procedures numbers were estimated even higher, with 81.5%. Although it was shown that standard head and neck cancer therapy is safe and need not to be withheld during the pandemic, recent data on nasopharyngeal carcinomas indicated a pandemic-related delay in the diagnostic pathway and treatment initiation. For the entity of sinonasal malignancies, there is a lack of data concerning tumor stage migration in the pandemic era. Sinonasal malignancies represent 3% to 5% of all head and neck cancers and their growth is associated with potential affection of pivotal neurovascular structures, such as brain, dura, carotid artery, and optic nerve. Typically, patients present at an advanced stage, since the tumor expands unnoticed for a long time and often leads to alarming symptoms at an advanced stage. Despite evolvement of new treatment strategies, namely advanced transnasal-endoscopic surgical techniques and high precision RT, 5-year OS and local control rates in the prepandemic era plateaued around 58% to 68%. Our study cohort reflects the last 3 years of newly diagnosed sinonasal malignancies at a tertiary referral center in Switzerland. Review of initial T classification revealed locally advanced tumors in the vast majority of all subjects (29/39 patients ≥ cT3). As various series have shown, tumor stage strongly predicts prognosis in sinonasal tumors, since especially tumors staged as T4b, with involvement of dura and/or brain, go along with poor DFS and OS. Accordingly, for nasopharyngeal carcinomas OS significantly depends on initial T category, with 5-year survival rates of 91% reported for T1 tumors vs 68% for T4 tumors.

Pandemic associated reasons for a potential diagnostic delay in cancer care are manifold and include (a) patient’s fear of contacts with health care providers, which lead to less patient visits during the pandemic (b) patients are concerned that potential healthcare-capacity issues may interfere with the optimal treatment of their disease, (c) lower participation or downregulation of screening programs, and (d) delayed referral from primary care to specialist and tertiary referral center. Turri-Zanoni et al recently published on the management of patients with sinonasal tumors during the pandemic and set a list of five recommendations, among which avoidance of a delay in diagnosis was named as first point. Thereby, they opted for prompt radiological assessment of the patient to define the extension of the cancer and recommended an endoscopic-assisted transnasal biopsy of the tumor. In contrast to the previous mentioned data from the UK and the Netherlands, the absolute number of newly diagnosed sinonasal tumors at our department was not lower in 2020, when compared to the two previous years. Also, we found no diagnostic delay from onset of first symptoms (as documented in the patient’s medical history) to diagnosis and treatment initiation. However, an indirect delay due to an irrational patient’s fear of contact with health care providers may have translated into an increased proportion of advanced tumor stages (36.7% ≥ stage 4 in 2018-2019 vs 63.2% ≥
stage 4 in 2020). Interestingly, despite the pandemic, we managed to initiate treatment even quicker, when compared to the era 2018 to 2019. This also included a virtual interdisciplinary tumor board decision. This finding might be explained by an increased awareness of potential prehospital diagnostic delay and a streaming of pivotal cases at a tertiary referral center due to postponement of elective cases. With regard to possible learnt lessons from the current situation, the pandemic forces the health care system to use alternative ways of cancer patient care, such as telemedicine. These technologies must be empowered, to serve as adjunct to patient screening, therapy planning, and follow-up.²⁷

4.2 | Limitations

Besides its retrospective design, we acknowledge that our study has some noteworthy limitations. First, we included all newly diagnosed sinonasal tumors in 2020, a post-hoc power analysis at an alpha level of .05 revealed, that our study was underpowered (21.4%). Second, we included three different rhinologic tumor entities in our cohort, which exhibit a different biological behavior. However, distribution of those three tumor entities was similar between the prepandemic and the pandemic group. Third, the follow up, in particular of the pandemic group, is too short to provide reliable statements in terms of outcome. Fourth, the pandemic itself had its course of lockdowns, exertion, and loosened periods, which could bias our results. Thus, further studies on larger cohorts are necessary to better understand the impact of the COVID-19 pandemic on sinonasal malignancies and head and neck cancer care in general.

4.3 | Conclusion

Absolute time to diagnosis and time to treatment initiation were similar during the pandemic, when compared to prepandemic era. A trend toward an increased proportion of advanced tumors as an indirect indicator of a diagnostic delay was observed, bearing the risk of a poorer outcome. Despite the pandemic, we were able to provide a targeted and swift diagnostic workflow, including a virtual tumor board decision. This effort even resulted in a decreased time from first appointment to treatment initiation at our institution.

CONFLICT OF INTEREST

The authors declare no potential conflict of interest.

ORCID

Christian M. Meerwein  
https://orcid.org/0000-0002-8674-1007

Thomas M. Stadler  
https://orcid.org/0000-0002-1262-0720

Panagiotis Balermpas  
https://orcid.org/0000-0001-5261-6446

Michael B. Soyka  
https://orcid.org/0000-0003-4179-4989

David Holzmann  
https://orcid.org/0000-0002-8176-8358

BIBLIOGRAPHY

1. Rosenbaum L. The untold toll—the Pandemic’s effects on patients without Covid-19. N Engl J Med. 2020;382(24):2368-2371. https://doi.org/10.1056/nejmjs2009984

2. Jones D, Neal RD, Duffy SRG, Scott SE, Whitaker KL, Brain K. Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care. Lancet Oncol. 2020;21(6):748-750. https://doi.org/10.1016/S1470-2045(20)30242-4

3. Neal RD, Nekhlyudov L, Wheatstone P, Koczwar B. Cancer care during and after the pandemic. BMJ. 2020;370:m2622. https://doi.org/10.1136/bmj.m2622

4. Kaufman HW, Chen Z, Niles J, Fesko Y. Changes in the number of US patients with newly identified cancer before and during the coronavirus disease 2019 (COVID-19) pandemic. JAMA Netw Open. 2020;3(8):e2017267. https://doi.org/10.1001/jamanetworkopen.2020.17267

5. Dinmohamed AG, Visser O, Verhoeven RHA, et al. Fewer cancer diagnoses during the COVID-19 epidemic in The Netherlands. Lancet Oncol. 2020;21(6):750-751. https://doi.org/10.1016/S1470-2045(20)30265-5

6. Xiao R, Ward MC, Yang K, et al. Unexpected increase of primary care screenings for cancer in the COVID-19 pandemic. JAMA. 2021;325(18):1812-1818. https://doi.org/10.1001/jama.2021.6727

7. Graboyes EM, Kompelli AR, Neskey DM, et al. Association of treatment delays with survival for patients with head and neck cancer: a systematic review. JAMA Otolaryngol-Head Neck Surg. 2019;145(2):166-177. https://doi.org/10.1001/jamaoto.2018.2716

8. Riva G, Pizzo C, Fassone E, Pecorari G. Head and neck cancer surgery in COVID-19 pandemic in northern Italy. Oral Oncol. 2020;107:104835. https://doi.org/10.1016/j.oraloncology.2020.104835

9. Werner MT, Carey RM, Albergotti WG, Lukens JN, Brody RM. Impact of the COVID-19 pandemic on the management of head and neck malignancies. Otolaryngol - Head Neck Surg (United States). 2020;162(6):816-817. https://doi.org/10.1177/0194599820921413

10. Bierley JD, Gospodorovicz MK, Witekiewicz C, eds. TNM Classification of Malignant Tumours. 8th ed. Hoboken, New Jersey, US: Wiley; 2017:2017.

11. Wang QQ, Berger NA, Xu R. Analyses of risk, racial disparity, and outcomes among US patients with Cancer and COVID-19 infection. JAMA Oncol. 2021;7(2):220-227. https://doi.org/10.1001/jamaoncol.2020.6178

12. Yang Y, Shen C, Hu C. Effect of COVID-19 epidemic on delay of diagnosis and treatment path for patients with nasopharyngeal carcinoma. Cancer Manag Res. 2020;12:3859-3864. https://doi.org/10.2147/CMAR.S254093

13. Nepogodiev D, Omar OM, Glasbey JC, et al. Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans. Br J Surg. 2020;107(11):1440-1449. https://doi.org/10.1002/bjs.11746

14. Thomson DJ, Palma D, Guckenberger M, et al. Practice recommendations for risk-adapted head and neck Cancer radiation therapy during the COVID-19 pandemic: an ASTRO-ESTRO consensus statement. Int J Radiat Oncol Biol Phys. 2020;107(4):618-627. https://doi.org/10.1016/j.ijrobp.2020.04.016

15. Turner JH, Reh DD. Incidence and survival in patients with sinonasal cancer: a historical analysis of population-based data. Head Neck. 2012;34(6):677-885. https://doi.org/10.1002/hed.21830

16. Lombardi D, Bottazzoli M, Turri-Zanoni M, et al. Sinonasal mucosal melanoma: A 12-year experience of 58 cases. Head and Neck. 2016;38(Suppl 1):E1737-E1745. https://doi.org/10.1002/hed.24309

17. Turri-Zanoni M, Battaglia P, Karl/kgiots A, Locatelli D, Castelnuovo P. Managing care for patients with sinonasal and anterior skull base cancers during the COVID-19 pandemic. Head and Neck. 2020;42:1503-1506. https://doi.org/10.1002/hed.26257
18. Miglani A, Patel SH, Kosiorek HE, Hinni ML, Hayden RE, Lal D. Endoscopic resection of sinonasal mucosal melanoma has comparable outcomes to open approaches. *Am J Rhinol Allergy*. 2017;31(3):200-204. https://doi.org/10.2500/ajra.2017.31.4435
19. Camp S, Van Gerven L, Vander PV, et al. Long-term follow-up of 123 patients with adenocarcinoma of the sinonasal tract treated with endoscopic resection and postoperative radiation therapy. *Head Neck*. 2016;38(2):294-300. https://doi.org/10.1002/hed.23900
20. Dulguerov P, Jacobsen MS, Allal AS, Lehmann W, Calcaterra T. Nasal and paranasal sinus carcinoma: are we making progress? A series of 220 patients and a systematic review. *Cancer*. 2001;92(12):3012-3029. https://doi.org/10.1002/1097-0142(20011215)92:12<3012::AID-CNCR10131>3.0.CO;2-E
21. Meccariello G, Deganello A, Choussy O, et al. Endoscopic nasal versus open approach for the management of sinonasal adenocarcinoma: a pooled-analysis of 1826 patients. *Head and Neck*. 2016;38(Suppl 1):E2267-E2274. https://doi.org/10.1002/hed.24182
22. Howlander N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review 1975-2016. Natl Cancer Institute Published Online 2019.
23. Wu LR, Liu YT, Jiang N, et al. Ten-year survival outcomes for patients with nasopharyngeal carcinoma receiving intensity-modulated radiotherapy: an analysis of 614 patients from a single center. *Oral Oncol*. 2017;69:26-32. https://doi.org/10.1016/j.joraloncology.2017.03.015
24. Bakouny Z, Paciotti M, Schmidt AL, Lipsitz SR, Choueiri TK, Trinh QD. Cancer screening tests and Cancer diagnoses during the COVID-19 pandemic. *JAMA Oncol*. 2021;7(3):458-460. https://doi.org/10.1001/jamaoncol.2020.7600
25. van de Haar J, Hoes LR, Coles CE, et al. Caring for patients with cancer in the COVID-19 era. *Nat Med*. 2020;26(5):665-671. https://doi.org/10.1038/s41591-020-0874-8
26. Meerwein CM, Pazahr S, Soyka MB, Hüllner MW, Holzmann D. Diagnostic accuracy of computed tomography and magnetic resonance imaging compared to surgical exploration for anterior skull base and medial orbital wall infiltration in advanced sinonasal tumors. *Head Neck*. 2020;42(8):2002-2012. https://doi.org/10.1002/hed.26129
27. Prasad A, Carey RM, Rajasekaran K. Head and neck virtual medicine in a pandemic era: lessons from COVID-19. *Head Neck*. 2020;42(6):1308-1309. https://doi.org/10.1002/hed.26174

How to cite this article: Meerwein CM, Stadler TM, Balermpas P, Soyka MB, Holzmann D. Diagnostic pathway and stage migration of sinonasal malignancies in the era of the COVID-19 pandemic. Laryngoscope Investigative Otolaryngology. 2021;6(5):904-910. doi:10.1002/lio2.640